Simulations Plus, Inc. operates through two primary segments: Software and Services. The Software segment features flagship products such as GastroPlus, ADMET Predictor, DILIsym, and MonolixSuite, which are used for physiologically based pharmacokinetic (PBPK) modeling, quantitative systems pharmacology, and population modeling. The Services segment provides consulting and contract research, including clinical trial simulations, data programming, and regulatory submission support. The company's software solutions are designed to reduce research and development costs by predicting drug absorption, distribution, metabolism, excretion, and toxicity (ADMET) in silico. Its technology is utilized by major pharmaceutical companies, biotechnology firms, and regulatory agencies worldwide, with a significant portion of its revenue generated in the United States, EMEA, and Asia Pacific regions.
